OPTN OptiNose, Inc. Stock Quote

OPTN [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-2.20	Insider Own	0.90%	Shs Outstand	48.91M	Perf Week	-3.21%
Market Cap	211.56M	Forward P/E	-	EPS next Y	-1.35	Insider Trans	-40.66%	Shs Float	27.89M	Perf Month	-1.51%
Income	-100.90M	PEG	-	EPS next Q	-0.46	Inst Own	90.90%	Short Float	16.92%	Perf Quarter	-8.20%
Sales	43.90M	P/S	4.82	EPS this Y	2.00%	Inst Trans	-3.54%	Short Ratio	10.02	Perf Half Y	-13.94%
Book/sh	0.57	P/B	6.88	EPS next Y	34.80%	ROA	-59.30%	Target Price	-	Perf Year	-36.77%
Cash/sh	2.65	P/C	1.48	EPS next 5Y	-	ROE	-294.60%	52W Range	3.14 - 10.00	Perf YTD	-5.31%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-75.50%	52W High	-61.50%	Beta	1.03
Dividend %	-	Quick Ratio	3.80	Sales past 5Y	-	Gross Margin	83.20%	52W Low	22.61%	ATR	0.23
Employees	102	Current Ratio	4.00	Sales Q/Q	24.20%	Oper. Margin	-	RSI (14)	37.42	Volatility	5.34% 5.47%
Optionable	No	Debt/Eq	3.79	EPS Q/Q	37.60%	Profit Margin	-	Rel Volume	4.08	Prev Close	3.92
Shortable	Yes	LT Debt/Eq	3.79	Earnings	Mar 03 BMO	Payout	-	Avg Volume	471.12K	Price	3.85
Recom	1.80	SMA20	-10.85%	SMA50	-9.65%	SMA200	-16.45%	Volume	1,005,130	Change	-1.79%

Dec-18-19

Initiated

Cowen

Outperform

$25

Aug-08-18

Initiated

Cantor Fitzgerald

Overweight

Mar-03-21 08:15AM	OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM	Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights GlobeNewswire
06:15AM	OptiNose, Inc. to Host Earnings Call ACCESSWIRE
Mar-02-21 10:06AM	Earnings Preview for OptiNose Benzinga
Feb-17-21 05:23PM	Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results GlobeNewswire -7.46%
Jan-25-21 04:30PM	Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +8.27%
Dec-21-20 10:00AM	Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-11-20 05:35PM	Is OPTN A Good Stock To Buy Now? Insider Monkey
Dec-01-20 04:30PM	Optinose Announces Changes to Board of Directors GlobeNewswire
Nov-18-20 08:33AM	OptiNose (OPTN) Looks Good: Stock Adds 6.2% in Session Zacks +8.74%
Nov-17-20 10:42AM	RBC Predicts Over 100% Rally for These 3 Stocks TipRanks +6.19%
Nov-07-20 09:31AM	OptiNose, Inc. (OPTN) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 07:00AM	Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights GlobeNewswire +11.42%
06:15AM	OptiNose, Inc. to Host Earnings Call ACCESSWIRE
Oct-22-20 07:00AM	Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million GlobeNewswire
Sep-29-20 09:30AM	New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays PR Newswire
Sep-14-20 08:00AM	Optinose to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire
Aug-14-20 01:11PM	Why Sunnova Energy, Rimini Street, and OptiNose Stocks All Dropped Today Motley Fool -21.96%
08:37AM	Optinose's stock plunges after stock offering prices at discount MarketWatch
08:04AM	Optinose Announces Pricing of Public Offering of Common Stock GlobeNewswire
Aug-13-20 04:26PM	Optinose Announces Proposed Public Offering of Common Stock GlobeNewswire
Aug-11-20 12:21PM	Is OptiNose (NASDAQ:OPTN) Using Too Much Debt? Simply Wall St. -5.94%
12:14PM	Health Check: How Prudently Does OptiNose (NASDAQ:OPTN) Use Debt? Simply Wall St.
Aug-05-20 12:30AM	OptiNose, Inc. (OPTN) Q2 2020 Earnings Call Transcript Motley Fool
Aug-04-20 09:15AM	OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates Zacks +12.43%
07:00AM	Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights GlobeNewswire
Jul-30-20 04:01PM	Optinose Announces Reporting Date for Second Quarter 2020 Financial Results GlobeNewswire
Jul-29-20 04:01PM	Optinose names Catherine E. Owen as Director GlobeNewswire +6.09%
Jul-16-20 03:27PM	3 Strong Buy Penny Stocks That Could Rally to $10 (Or More) TipRanks
Jul-09-20 08:09AM	The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio Benzinga
Jul-05-20 03:05PM	Here is What Hedge Funds Think About OptiNose, Inc. (OPTN) Insider Monkey
Jun-30-20 08:00AM	Optinose Announces Anti-COVID-19 Product Candidate GlobeNewswire +15.89%
Jun-22-20 08:30AM	Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-19-20 10:00AM	Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal GlobeNewswire +5.38%
May-27-20 04:30PM	Optinose to Host its Annual Meeting of Stockholders in Virtual Format GlobeNewswire -5.82%
May-26-20 09:00AM	Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference GlobeNewswire
May-14-20 04:15PM	Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference GlobeNewswire -5.11%
May-08-20 03:00PM	OptiNose, Inc. (OPTN) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 04:01PM	Optinose Reports First Quarter 2020 Financial Results and Operational Updates GlobeNewswire
Apr-30-20 04:15PM	Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020 GlobeNewswire
Apr-29-20 08:47AM	Analyst Forecasts Just Got A Whole Lot More Bearish On OptiNose, Inc. (NASDAQ:OPTN) Simply Wall St.
Apr-11-20 10:01AM	Does OptiNose, Inc. (NASDAQ:OPTN) Have A High Beta? Simply Wall St.
Mar-16-20 09:15AM	Moving Average Crossover Alert: OptiNose Zacks -20.25%
Mar-05-20 07:45AM	OptiNose (OPTN) Reports Q4 Loss, Misses Revenue Estimates Zacks -8.10%
06:30AM	Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights GlobeNewswire
Feb-27-20 04:30PM	Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020 GlobeNewswire
Feb-26-20 12:30PM	Earnings Preview: OptiNose (OPTN) Q4 Earnings Expected to Decline Zacks
Feb-19-20 07:00AM	Optinose Appoints Victor Clavelli as Chief Commercial Officer GlobeNewswire
Dec-17-19 07:03PM	Hedge Funds Have Never Been This Bullish On OptiNose, Inc. (OPTN) Insider Monkey -5.02%
08:30AM	Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial GlobeNewswire
Dec-10-19 12:12PM	Read This Before Selling OptiNose, Inc. (NASDAQ:OPTN) Shares Simply Wall St. +8.28%
Nov-26-19 04:01PM	Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-21-19 09:00AM	Optinose Announces Pricing of Public Offering of Common Stock GlobeNewswire -17.62%
Nov-20-19 04:00PM	Optinose Announces Proposed Public Offering of Common Stock GlobeNewswire +7.74%
Nov-17-19 08:00AM	How health startup Optinose engineered a 300%+ spike in growth Yahoo Finance
Nov-12-19 04:01PM	Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights GlobeNewswire -6.09%
Nov-07-19 06:02PM	Hedge Funds Have Never Been More Bullish On OptiNose, Inc. (OPTN) Insider Monkey +5.85%
Nov-05-19 10:33AM	Earnings Preview: OptiNose (OPTN) Q3 Earnings Expected to Decline Zacks
Nov-01-19 08:00AM	Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019 GlobeNewswire +8.95%
Oct-04-19 08:00AM	Optinose Appoints Michael Richardson to New Position of Vice President, Business Development Globenewswire Test
08:00AM	Optinose Appoints Michael Richardson to New Position of Vice President, Business Development GlobeNewswire
Sep-27-19 08:00AM	Optinose to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-26-19 08:15AM	Currax Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail® PR Newswire
07:00AM	OptiNose Announces License Agreement Related to ONZETRA XSAIL GlobeNewswire
Sep-17-19 04:01PM	Optinose Announces Departure of Chief Commercial Officer GlobeNewswire +7.44%
Sep-12-19 04:05PM	Optinose Announces $150 Million Debt Financing from Pharmakon GlobeNewswire
Sep-11-19 01:34PM	Is OptiNose (NASDAQ:OPTN) Using Debt In A Risky Way? Simply Wall St.
Aug-13-19 03:45PM	OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says Benzinga +11.59%
Aug-12-19 10:23PM	OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript Motley Fool +8.30%
05:25PM	OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:02PM	Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights GlobeNewswire
02:30PM	OptiNose, Inc. to Host Earnings Call ACCESSWIRE
Aug-05-19 10:30AM	Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for Zacks -5.19%
Aug-01-19 04:30PM	Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019 GlobeNewswire
Jul-11-19 12:13PM	Those Who Purchased OptiNose (NASDAQ:OPTN) Shares A Year Ago Have A 73% Loss To Show For It Simply Wall St.
Jun-20-19 08:00AM	Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire +8.54%
Jun-19-19 04:30PM	Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal GlobeNewswire +5.22%
May-22-19 10:42AM	You Can Get Buy Signals From Short Selling InvestorPlace
May-09-19 11:23AM	OptiNose, Inc. (OPTN) Q1 2019 Earnings Call Transcript Motley Fool -14.27%
08:55AM	OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:46AM	OptiNose: 1Q Earnings Snapshot Associated Press
07:00AM	Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights GlobeNewswire
May-02-19 10:33AM	OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-27-19 09:01AM	Have Insiders Been Buying OptiNose, Inc. (NASDAQ:OPTN) Shares? Simply Wall St.
Apr-25-19 07:00AM	Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019 GlobeNewswire
Mar-21-19 11:06AM	OptiNose Analysts Projects Prescription Growth In 2019, Beyond Benzinga
Mar-06-19 12:22PM	OptiNose, Inc. (OPTN) Q4 2018 Earnings Conference Call Transcript Motley Fool -5.76%
07:00AM	Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights GlobeNewswire
Feb-27-19 07:00AM	Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019 GlobeNewswire
Feb-19-19 07:00AM	Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE GlobeNewswire
Feb-15-19 07:00AM	Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco GlobeNewswire
Feb-04-19 12:46PM	Bucks County drug-device developer inks licensing deal worth a potential $45M American City Business Journals +6.36%
07:00AM	Optinose Announces License Agreement GlobeNewswire
Dec-25-18 10:28AM	OptiNose, Inc. (NASDAQ:OPTN): Time For A Financial Health Check Simply Wall St.
Dec-13-18 07:56AM	The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen Benzinga +8.99%
Dec-11-18 07:50AM	Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group Discovering Underlying Factors of Influence GlobeNewswire
07:00AM	Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL GlobeNewswire
Dec-10-18 07:00AM	Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis GlobeNewswire
Dec-05-18 04:30PM	Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-26-18 05:29PM	Is OptiNose, Inc. (NASDAQ:OPTN) A Good Stock To Buy? Insider Monkey -5.49%

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mahmoud Ramy A	President and COO	Dec 23	Option Exercise	1.63	28,342	46,197	54,573	Dec 29 05:44 PM
Mahmoud Ramy A	President and COO	Dec 23	Option Exercise	1.63	85,016	138,576	216,504	Dec 29 05:44 PM
Miller Peter K	Chief Executive Officer	Dec 23	Option Exercise	1.63	86,639	141,222	162,359	Dec 29 05:43 PM
Miller Peter K	Chief Executive Officer	Dec 23	Option Exercise	1.63	140,068	228,311	395,085	Dec 29 05:43 PM
Mahmoud Ramy A	President and COO	Dec 23	Sale	4.03	7,835	31,607	46,738	Dec 29 05:44 PM
Mahmoud Ramy A	President and COO	Dec 23	Sale	4.03	23,436	94,546	193,068	Dec 29 05:44 PM
Miller Peter K	Chief Executive Officer	Dec 23	Sale	4.03	23,863	96,177	138,496	Dec 29 05:43 PM
Miller Peter K	Chief Executive Officer	Dec 23	Sale	4.03	38,591	155,537	356,494	Dec 29 05:43 PM
Miller Peter K	Chief Executive Officer	Dec 02	Option Exercise	1.63	102,268	166,697	142,638	Dec 04 05:43 PM
Miller Peter K	Chief Executive Officer	Dec 02	Option Exercise	1.63	121,812	198,554	334,540	Dec 04 05:43 PM
Miller Peter K	Chief Executive Officer	Dec 02	Sale	4.32	33,330	143,996	109,308	Dec 04 05:43 PM
Miller Peter K	Chief Executive Officer	Dec 02	Sale	4.33	41,470	179,395	293,070	Dec 04 05:43 PM
Miller Peter K	Chief Executive Officer	Nov 25	Option Exercise	1.63	18,393	29,981	52,539	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 25	Option Exercise	1.63	37,985	61,916	237,860	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 25	Option Exercise	1.63	3,489	5,687	28,899	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 25	Option Exercise	1.63	10,467	17,061	142,191	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 25	Sale	4.32	977	4,216	27,922	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 25	Sale	4.32	2,931	12,649	139,260	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 25	Sale	4.30	5,141	22,118	47,398	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 25	Sale	4.30	10,617	45,678	227,243	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 24	Option Exercise	1.63	16,302	26,572	44,867	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 24	Option Exercise	1.63	33,653	54,854	222,007	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 24	Option Exercise	1.63	12,496	20,368	33,627	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 24	Option Exercise	1.63	37,466	61,070	156,363	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 24	Sale	4.39	3,533	15,494	30,094	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 24	Sale	4.39	10,593	46,455	145,770	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 24	Sale	4.39	4,609	20,212	40,258	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 24	Sale	4.39	9,515	41,727	212,492	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 23	Option Exercise	1.63	62,488	101,855	69,334	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 23	Option Exercise	1.63	129,021	210,304	272,531	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 23	Option Exercise	1.63	47,898	78,074	52,381	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 23	Option Exercise	1.63	143,611	234,086	212,593	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 23	Sale	4.50	13,746	61,852	38,635	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 23	Sale	4.50	41,214	185,447	171,379	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 23	Sale	4.50	17,933	80,691	51,401	Nov 25 07:27 PM
Miller Peter K	Chief Executive Officer	Nov 23	Sale	4.50	37,027	166,607	235,504	Nov 25 07:27 PM
Mahmoud Ramy A	President and COO	Nov 19	Option Exercise	1.63	1,406	2,292	5,365	Nov 20 04:11 PM
Mahmoud Ramy A	President and COO	Nov 19	Option Exercise	1.63	4,212	6,866	71,635	Nov 20 04:11 PM
Miller Peter K	Chief Executive Officer	Nov 19	Option Exercise	1.63	2,147	3,500	8,192	Nov 20 04:11 PM
Miller Peter K	Chief Executive Officer	Nov 19	Option Exercise	1.63	3,471	5,658	145,704	Nov 20 04:11 PM
Mahmoud Ramy A	President and COO	Nov 19	Sale	5.06	1,285	6,506	70,350	Nov 20 04:11 PM
Miller Peter K	Chief Executive Officer	Nov 19	Sale	5.06	655	3,316	7,537	Nov 20 04:11 PM
Miller Peter K	Chief Executive Officer	Nov 19	Sale	5.06	1,059	5,362	144,645	Nov 20 04:11 PM
Mahmoud Ramy A	President and COO	Nov 18	Option Exercise	1.63	3,278	5,343	6,022	Nov 20 04:11 PM
Mahmoud Ramy A	President and COO	Nov 18	Option Exercise	1.63	9,819	16,005	73,638	Nov 20 04:11 PM
Miller Peter K	Chief Executive Officer	Nov 18	Option Exercise	1.63	5,005	8,158	9,194	Nov 20 04:11 PM
Miller Peter K	Chief Executive Officer	Nov 18	Option Exercise	1.63	8,091	13,188	147,356	Nov 20 04:11 PM
Miller Peter K	Chief Executive Officer	Nov 18	Sale	5.00	1,518	7,590	7,676	Nov 20 04:11 PM
Miller Peter K	Chief Executive Officer	Nov 18	Sale	5.00	2,454	12,270	144,902	Nov 20 04:11 PM
Mahmoud Ramy A	President and COO	Nov 18	Sale	5.00	994	4,970	5,028	Nov 20 04:11 PM
Mahmoud Ramy A	President and COO	Nov 18	Sale	5.00	2,978	14,890	70,660	Nov 20 04:11 PM
Goldan Keith A.	Chief Financial Officer	Sep 23	Buy	3.90	2,500	9,743	9,751	Sep 23 04:47 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Sep 04	Buy	4.25	1,000	4,250	17,570	Sep 09 02:53 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Sep 01	Buy	4.30	1,000	4,300	16,570	Sep 09 02:53 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Aug 21	Buy	5.03	1,000	5,030	15,570	Aug 25 02:00 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Aug 20	Buy	5.25	1,000	5,250	14,570	Aug 25 02:00 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Aug 18	Buy	5.10	500	2,550	13,003	Aug 18 06:49 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Aug 17	Buy	5.21	2,000	10,410	12,503	Aug 18 06:49 PM
Marino Michael F III	Chief Legal Officer & Corp Sec	Aug 14	Buy	5.10	3,567	18,201	13,570	Aug 18 06:49 PM
Mahmoud Ramy A	President and COO	Aug 11	Option Exercise	1.63	4,861	7,923	5,567	Aug 12 07:27 PM
Mahmoud Ramy A	President and COO	Aug 11	Option Exercise	1.63	14,549	23,715	72,268	Aug 12 07:27 PM
Miller Peter K	Chief Executive Officer	Aug 11	Option Exercise	1.63	7,425	12,103	8,500	Aug 12 07:26 PM
Miller Peter K	Chief Executive Officer	Aug 11	Option Exercise	1.63	11,988	19,540	146,227	Aug 12 07:26 PM
Miller Peter K	Chief Executive Officer	Aug 11	Sale	7.00	2,562	17,944	5,938	Aug 12 07:26 PM
Miller Peter K	Chief Executive Officer	Aug 11	Sale	7.00	4,138	28,983	142,089	Aug 12 07:26 PM
Mahmoud Ramy A	President and COO	Aug 11	Sale	7.00	1,678	11,753	3,889	Aug 12 07:27 PM
Mahmoud Ramy A	President and COO	Aug 11	Sale	7.00	5,022	35,174	67,246	Aug 12 07:27 PM
Mahmoud Ramy A	President and COO	Aug 10	Option Exercise	1.63	1,682	2,742	1,682	Aug 12 07:27 PM
Mahmoud Ramy A	President and COO	Aug 10	Option Exercise	1.63	5,022	8,186	60,637	Aug 12 07:27 PM
Miller Peter K	Chief Executive Officer	Aug 10	Option Exercise	1.63	2,562	4,176	2,562	Aug 12 07:26 PM
Miller Peter K	Chief Executive Officer	Aug 10	Option Exercise	1.63	4,140	6,748	136,645	Aug 12 07:26 PM
Miller Peter K	Chief Executive Officer	Aug 10	Sale	7.00	884	6,188	1,678	Aug 12 07:26 PM
Miller Peter K	Chief Executive Officer	Aug 10	Sale	7.00	1,429	10,003	135,216	Aug 12 07:26 PM
Mahmoud Ramy A	President and COO	Aug 10	Sale	7.00	580	4,060	1,102	Aug 12 07:27 PM
Mahmoud Ramy A	President and COO	Aug 10	Sale	7.00	1,733	12,131	58,904	Aug 12 07:27 PM
O'Neil Robert P	Director	Mar 09	Buy	5.32	5,000	26,596	7,000	Mar 09 04:33 PM
Scodari Joseph C	Director	Mar 06	Buy	5.70	8,700	49,605	21,230	Mar 09 07:07 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience